InsidersTradesSigma
EUROBIO-SCIENTIFIC: directors' dealings · France · AMF
RS00004121FR0013240934FR·AMFMcap 228M€Healthcare & Pharma
Explore the full directors' dealings record of EUROBIO-SCIENTIFIC, a listed issuer based in France. Shares are quoted on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, EUROBIO-SCIENTIFIC has recorded 39 public disclosures. Market capitalisation: €227.5m. The latest transaction was disclosed on 6 December 2024 (Apport à une offre publique d'acquisition). Among the most active insiders: Denis FORTIER. All data is accessible without an account.
39
Insider Decl.
0
Thresholds
€6m
5 ops.
Buy Volume
€6m
18 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
22.60 €
Analyst consensus
1 analysts1.00/5
30.00 €Target 30.00 €(+33%)30.00 €
Income statement
Revenue168.6 M€
Gross profit76.8 M€46% margin
Net income4.9 M€2.9% margin
Valuation
PER (trailing)48.1x
P/Book1.3x
Beta0.72
Balance sheet & cash
Market cap227.5 M€
Total debt16.0 M€
Free Cash Flow6.3 M€
Profitability & ownership
% insiders0.1%
% institutions97.6%
Last declaration on 6 December 2024
Declarations39 total
Executives▲Purchase43AMF
€87,2853,450 shares@ €25.300.034% mcap100.0% of flow
ActionEuronext Growth Paris
2024DD1009986·
Ideal exit: 1 Sept 2025 (T+270)
Executives▲Purchase43AMF
€91,9153,633 shares@ €25.300.036% mcap15.0% of flow
ActionEuronext Growth Paris
2024DD1009990·
Ideal exit: 1 Sept 2025 (T+270)
Executives▲Purchase◆Signal · 50AMF
€74,8882,960 shares@ €25.300.030% mcap100.0% of flow
ActionEuronext Growth Paris
2024DD1009998·
Ideal exit: 1 Sept 2025 (T+270)
Executives●Apport en nature24AMF
€88m3,488,265 shares@ €25.3094.2% of flow
ActionEuronext Growth Paris
2024DD1010001·
Executives▲Purchase41AMF
€146,0825,774 shares@ €25.300.058% mcap0.3% of flow
ActionEuronext Growth Paris
2024DD1009982·
Ideal exit: 1 Sept 2025 (T+270)
Executives▲Purchase18AMF
€30,3402,000 shares@ €15.170.012% mcap0.1% of flow
ActionEuronext Growth Paris
2023DD943585·
Ideal exit: 13 Sept 2024 (T+270)
Executives▲Purchase21AMF
€1,61097 shares@ €16.600.0006% mcap0.0% of flow
ActionEuronext Growth Paris
2022DD875203·
Ideal exit: 1 Aug 2023 (T+270)
Executives▲Purchase19AMF
€16,6701,000 shares@ €16.670.0066% mcap0.0% of flow
ActionEuronext Growth Paris
2022DD870243·
Ideal exit: 24 Jul 2023 (T+270)
Executives▲Purchase21AMF
€495,68428,100 shares@ €17.640.20% mcap0.5% of flow
ActionEuronext Growth Paris
2022DD860355·
Ideal exit: 5 Jun 2023 (T+270)
Executives▲Purchase28AMF
€5m281,000 shares@ €17.641.96% mcap5.3% of flow
ActionEuronext Growth Paris
2022DD860457·
Ideal exit: 5 Jun 2023 (T+270)
Executives●Apport40AMF
€24m25.28 shares@ €945,863.009.44% mcap48.5% of flow
ActionHors plateforme de négociation
2022DD843696·
Executives●Apport37AMF
€24m945,863 shares@ €25.289.44% mcap48.5% of flow
ActionHors plateforme de négociation
2022DD844115·
Executives●Apport33AMF
€46m1,822,772 shares@ €25.2818.19% mcap100.0% of flow
ActionHors plateforme de négociation
2022DD843699·
Executives▼Sale◆Signal · 49AMF
€500,01319,779 shares@ €25.280.20% mcap16.1% of flow
ActionHors plateforme de négociation
2022DD843701·
Executives▼Sale◆Signal · 53AMF
€1m51,423 shares@ €25.280.51% mcap41.9% of flow
ActionHors plateforme de négociation
2022DD843702·
Executives▼Sale◆Signal · 53AMF
€1m51,423 shares@ €25.280.51% mcap41.9% of flow
ActionHors plateforme de négociation
2022DD843703·
Executives▼Sale◆Signal · 51AMF
€292,16111,557 shares@ €25.280.12% mcap47.6% of flow
ActionHors plateforme de négociation
2022DD843704·
Executives▼Sale◆Signal · 45AMF
€101,1204,000 shares@ €25.280.040% mcap16.5% of flow
ActionHors plateforme de négociation
2022DD843705·
Executives●Apport40AMF
€22m876,909 shares@ €25.288.75% mcap97.5% of flow
ActionHors plateforme de négociation
2022DD843698·
Executives●Donation27AMF
019,779 shares0
ActionHors plateforme de négociation
2022DD836341·
Executives●Donation16AMF
016,461 shares0
ActionHors plateforme de négociation
2022DD836342·
Executives●Donation16AMF
0233,383 shares0
ActionHors plateforme de négociation
2022DD836343·
Executives●Donation16AMF
016,461 shares0
ActionHors plateforme de négociation
2022DD836345·
Executives●Donation16AMF
028,000 shares0
ActionHors plateforme de négociation
2022DD835391·
Executives●Donation16AMF
04,000 shares0
ActionHors plateforme de négociation
2022DD835439·
25 of 39 declarations
About EUROBIO-SCIENTIFIC
Eurobio Scientific is a French specialist in in vitro diagnostics and life sciences, listed on Euronext Growth Paris under the ticker ALERS and ISIN FR0013240934. The group operates as an integrated specialty diagnostics player, focused on the research, development, manufacturing and commercialization of tests and reagents used by laboratories, hospitals and research centers. Its portfolio is centered on three core clinical areas: infectious diseases, transplantation and oncology, alongside life-science research tools and quality-control solutions. The company’s development has been shaped by a series of strategic acquisitions and integrations. Eurobio Scientific was formed after Exonhit acquired Ingen in 2012 and later Eurobio in 2017, creating a broader platform in specialty diagnostics. Over time, the group has built recognized expertise in niche segments such as molecular biology, transplant diagnostics and laboratory quality control, combining proprietary products with exclusive distribution agreements for third-party technologies. From a product standpoint, Eurobio Scientific offers a diversified range of diagnostic and research solutions. Its portfolio includes molecular biology assays, infectious-disease test panels, autoimmunity solutions, culture media, and products for corneal graft transport and preservation. The company also distributes instruments and reagents for life-science research laboratories. This mix of proprietary and distributed products is an important competitive strength, supporting both differentiation and recurring revenues. Eurobio Scientific positions itself as a leading player in the French specialty IVD market, while maintaining a meaningful international footprint. The group is headquartered in the Paris region and has subsidiaries or affiliates in the United States, notably in San Diego and Chicago, as well as across several European countries including the UK, Germany, Switzerland, Belgium, the Netherlands and Italy. In 2024, international markets accounted for 41% of group revenue, confirming the company’s growing geographic diversification. Financially, 2024 highlighted the resilience of the core business, with revenue rising to €154.2 million, up 19%, and positive cash generation. Eurobio Scientific has also continued to execute a growth-by-acquisition strategy, including the EndoPredict oncology test and recent initiatives aimed at strengthening its transplantation franchise. Overall, the group’s strategic direction is clear: to build a larger, more proprietary and more international specialty diagnostics platform with a stronger position in high-value clinical niches.
